Download MendeleyIdentification of Dihydrobenzofuran Neolignans as Novel PDE4 Inhibitors and Evaluation of Antiatopic Dermatitis Efficacy in DNCB-Induced Mice Model.
Gu, C., Liu, J., Qian, F., Yu, W., Huang, D., Shen, J., Feng, C., Chen, K., Li, Y., Jiang, X., Xu, Y., Zhang, L.(2024) J Med Chem 67: 4855-4869
- PubMed: 38489246
- DOI: https://doi.org/10.1021/acs.jmedchem.3c02424
- Primary Citation of Related Structures:
8WDN, 8WDO - PubMed Abstract:
Atopic dermatitis is a chronic relapsing skin disease characterized by recurrent, pruritic, localized eczema, while PDE4 inhibitors have been reported to be effective as antiatopic dermatitis agents. 3',4- O -dimethylcedrusin (DCN) is a natural dihydrobenzofuran neolignan isolated from Magnolia biondii with moderate potency against PDE4 (IC 50 = 3.26 ± 0.28 μM) and a binding mode similar to that of apremilast, an approved PDE4 inhibitor for the treatment of psoriasis. The structure-based optimization of DCN led to the identification of 7b-1 that showed high inhibitory potency on PDE4 (IC 50 = 0.17 ± 0.02 μM), good anti-TNF-α activity (EC 50 = 0.19 ± 0.10 μM), remarkable selectivity profile, and good skin permeability. The topical treatment of 7b-1 resulted in the significant benefits of pharmacological intervention in a DNCB-induced atopic dermatitis-like mice model, demonstrating its potential for the development of novel antiatopic dermatitis agents.
Organizational Affiliation:
School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
